Message #34 From:
NewsBot Date: November 28, 2006 05:00:00 AM
EVSC News Endovasc Appoints Marketing and Branding Expert to its Board of Directors
MONTGOMERY, Texas--(BUSINESS WIRE)--Endovasc, Inc. - (OTCBB: EVSC),
a Business Development Company focused on acquiring and investing in
companies engaged in the development of innovative cardiovascular and
metabolic drugs, as well as nutraceutical supplements, is pleased to
announce the appointment of Mr. Thomas Hall to its Board of Directors,
effective November 28, 2006.
Mr. Hall is Founder, President & Chief Executive Officer of
BrandworksPartners LLC, a packaged goods firm focused on acquiring
midsize global brands for expansion in mass channels, primarily in the
United States and Europe. While in this position, he has achieved an
average annual sales growth rate of 36% for the company. Prior to
founding BrandworksPartners, Mr. Hall was the President & Chief
Operating Officer of Lansinoh Laboratories, a therapeutic lotions and
baby care products company, where he was responsible for the company’s
operating results, distribution and manufacturing, and was a member of
its Board of Directors.
Thomas Hall’s marketing experience commenced
at Procter & Gamble in Brand Management where he worked on advertising
and marketing strategies, pre-market qualification, packaging, and sales
force targeting on various brands such as Metamucil, Aleve, and Crest
Complete. While with Procter & Gamble, he led a $50 million product
introduction including a $25 million media campaign which resulted in a
record 15% market share in the United States. In addition, Mr. Hall was
instrumental in the prescription to over-the-counter switch of Naprosyn,
where he qualified the “All Day Strong”
positioning.
Following his experience with Procter & Gamble, Mr. Hall joined
Beiersdorf AG as the Director, Personal Healthcare Division where he was
responsible for marketing, financial performance, and product
development for a $60 million business including first-aid and baby care
products. Subsequently, he gained international experience by accepting
the role of Director, Medical Division in Athens, Greece where he led a
35 person team and was responsible for the marketing, manufacturing and
sales of therapeutic lotions, first aid, orthopedic, feminine hygiene,
and birth control brands.
Mr. Hall earned a B.S. in History/Asian studies at Cornell University
and subsequently earned his MBA in International Business at Georgetown
University, where he was a Beta Gamma Sigma Scholar. Currently, Mr. Hall
is an adjunct Professor at Northeastern University Business School and a
Trustee for the Scituate Historical Society as well as a member of the
Board of Directors at BrandworksPartners.
Dr. Diane Dottavio, President and Chief Executive Officer of Endovasc,
Inc., commented, “We are thrilled to add Tom
to our Board of Directors. His impressive and extensive marketing and
branding expertise will play a significant role in the identification of
new investments and management of our current portfolio companies. As
Liprostin, Inc. gets closer to commercialization of its liposomal
encapsulated Prostaglandin 1-E, Tom will help guide our business
strategy and marketing initiatives by lending his expertise from both an
operational and industry marketing perspective.”
About Endovasc, Inc.
Endovasc, Inc. is focused on investing in private companies and
developing and commercializing drug candidates in the areas of
cardiovascular and metabolic medicine. Endovasc is organized as a
business development company, and has invested in the following
subsidiaries: Liprostin Inc., which holds the intellectual property for
a liposomal based treatment to increase circulation and reduce leg pain
in patients suffering from vascular disease; Prostent, Inc., which is
developing a stent coating technology; and Nutraceutical Development
Corporation, which has developed marketed technology to increase muscle
mass.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain forward-looking
statements that involve risks and uncertainties that may not be evident
at the time of this release.
